Shots: The approval is based on P-III CLARITY study assessing Mavenclad vs PBO in 1,976 patients with RRMS and SPMS in adults P-III CLARITY study results: 58% reduction in the […]readmore
Tags : SPMS
Shots: The approval is based on P-III EXPAND study results assessing Mayzent vs PBO in 1,651 patients with SPMS from 31 countries aged 48yrs. P-III study results: reduction in risk […]readmore